Epcoritamab shows high rates of first-line response and MRD negativity in older patients with chemo-ineligible DLBCL, whether used alone or with R-mini-CHOP. Current sickle cell disease (SCD) trial ...
Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 ...
A 12-week prospective cohort enrolled 73 patients with guideline-based asthma or COPD and no speech-affecting comorbidities, ...
AHSCT resets the immune system in highly active RRMS after high-efficacy drugs fail, delivering higher NEDA, fewer relapses, and durable function gains. When high-efficacy drugs stop holding relapsing ...
Analyses spanning 35,245 patients across 13 scenarios found comparable initiation of any systemic therapy in Medicare ...
The FDA approved enlicitide (Lipfendra; Merck), the first oral PCSK9 inhibitor for lowering low-density lipoprotein ...
This study examines how key players in managed care drive postacute home health referrals, identifying tensions, limited ...
Deepak Bhatt, MD, MPH, MBA, discusses hot new topics reshaping care for diabetes, obesity, and cardiovascular disease. One example of this new era is the SURPASS-CVOT trial (NCT04255433), a ...
INCA033989 showed encouraging spleen, anemia, and molecular responses in mutant calreticulin myelofibrosis, suggesting ...
Restricting step-up dosing and acute triage to a defined T-cell engaging team improves safety and consistency, with patients transitioning back to primary oncologists after stabilization. Standardized ...
In the second and final part of her interview with The American Journal of Managed Care ® (AJMC ®), Cherie Daly, MD, director ...
In the final episode, 'Fixing the Mental Health System: Burnout, Advocacy, and the Case for Team-Based Care,' the panelists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results